This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.

Core Insights - Vaxcyte remains a top pick for Mizuho Securities as it approaches 2026, indicating strong confidence in the company's future performance [1] Company Summary - Vaxcyte is recognized for its innovative approach in the vaccine sector, which positions it favorably among investors [1] - The company is expected to continue its growth trajectory, supported by its robust pipeline and strategic initiatives [1] Industry Summary - The vaccine industry is experiencing significant advancements, with companies like Vaxcyte leading the way in innovation and development [1] - Mizuho Securities' endorsement reflects a positive outlook for the vaccine market, suggesting potential for substantial returns in the coming years [1]